BioSculpture Technology’s Disruptive New Treatment for Obesity and Type 2 Diabetes with Dr. Robert Cucin

302

Adam Torres and Robert Cucin MD JD MBA FACS discuss BioSculpture Technology’s new treatment.

Subscribe: iTunes / Spotify / Stitcher / RSS

Apply to be a guest on our podcast here

Show Notes:

BioSculpture Technology’s new treatment has the potential to dramatically improve the lives of those suffering from obesity and Type 2 diabetes. In this episode,  Adam Torres and Robert Cucin MD JD MBA FACS, Founder and CEO of BioSculpture Technology, explore BioSculpture Technology’s new disruptive treatment.  

About Robert Cucin MD JD MBA FACS

Goal: Guide and participate in the success of companies embarking upon worthy and promising projects for profit and society, concentrating on the medical and healthcare sectors. To make a favorable impact in these sectors beyond what I do with my own two hands as a plastic surgeon on a patient-by-patient basis.

Experience: Plastic & Reconstructive Surgeon; serial medical entrepreneur, life science and biotech principal investigator and research analyst, due diligence consultant for 25+ years. Peer-reviewed and published basic laboratory and clinical researcher and practitioner. Personally developing & profitably licensing over a dozen patents in this field for over 20 years; entrepreneur, investor and executive in this sector dealing with FDA, trademarks, ISO/CE/GMP controls. Building value in sectors of expertise.

About BioSculpture Technology, Inc.

BST’s Corporate Mission is to unleash the artist in the surgeon® and be a world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: the liposuction and body sculpting market; the bariatric market; and fat autograft and adipocyte-derived stem cell processing markets.

BST’s Obesity Control Division is developing minimally invasive medical devices and methods for endoscopic visceral lipectomy, the direct removal of intra-abdominal “belly fat” taught by its three recently granted U.S. patents and its EPO application.  These devices and methods have the potential for helping 1.3 Billion obese people about the globe suffering from obesity, metabolic syndrome, and type 2 diabetes mellitus.  We believe we can offer a safer and highly effective alternative to current surgical bariatric surgery treatments of obesity.

Apply to be a guest on our podcast here

Get the Mission Matters News FREE here

LEAVE A REPLY

Please enter your comment!
Please enter your name here